Summary
The product CUT BLEND 300, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN56429, was submitted by Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control.
The testing process began on 26 September 2022, with the sample received on 1 October 2022, and analysis completed on 14 October 2022. While the results confirm accurate dosing for this batch, scrutiny of reseller-submitted samples is essential to ensure reliability. Resellers may select specific batches that meet high-quality standards, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: CUT BLEND 300
- Active Ingredients:
- Drostanolone Propionate
- Trenbolone Acetate
- Testosterone Propionate
- Batch Number: UN56429
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #24389
- Testing Ordered: 26 September 2022
- Sample Received: 1 October 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
| Compound | Specification | Measured Concentration | Accuracy | Variance |
|---|---|---|---|---|
| Drostanolone Propionate | 100 mg/ml | 101.54 mg/ml | 101.54% | +1.54% |
| Trenbolone Acetate | 100 mg/ml | 93.74 mg/ml | 93.74% | -6.26% |
| Testosterone Propionate | 100 mg/ml | 96.13 mg/ml | 96.13% | -3.87% |
Verification Details
- Verification URL: [Click Here to Visit]
- Originally Published: [Click Here to Visit]
Evaluation of Reseller-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by the reseller Opitropin.EU. Resellers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that CUT BLEND 300 contains all declared compounds with slight variances from the labeled concentrations. This result reflects strong quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
